GREENFIELD - Greenfield-based Elanco Animal Health Inc. (NYSE: ELAN) has announced a global research and development partnership with Denmark-based Novozymes A/S. Elanco says the collaboration will develop nutritional health products for beef cattle and dairy cows throughout the world.

The goal of the partnership is to develop an R&D pipeline and commercialize products within the next decade. Elanco says identifying and developing new products to help manage the animals' microbiome, control infections, and reduce gut inflammation while decreasing the need for antibiotics is a top priority.

"Nutritional health is an exciting platform that will define the next generation of feed additives to improve the health and performance of food animals," said Aaron Schacht, executive vice president of innovation, regulatory and business development for Elanco. "This collaboration expands our growing nutritional health capability into cattle and underscores Elanco’s commitment to bring producers innovative alternatives to antibiotics, while preserving the health and welfare of the animal."

Elanco says it is looking to deliver 25 viable antibiotic alternative development projects by 2020 that address "critical unmet challenges in livestock production" as part of its 8-point Antibiotic Stewardship Plan released in 2015.